Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

JAMA

Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S.
PMID: 35015038
JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182.

IMPORTANCE: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown.OBJECTIVE: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a...

Cite
Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022;327(2):129-137doi: 10.1001/jama.2021.23182.
Goldenberg, N. A., Kittelson, J. M., Abshire, T. C., Bonaca, M., Casella, J. F., Dale, R. A., Halperin, J. L., Hamblin, F., Kessler, C. M., Manco-Johnson, M. J., Sidonio, R. F., Spyropoulos, A. C., Steg, P. G., Turpie, A. G. G., Schulman, S. (2022). Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA, 327(2), 129-137. https://doi.org/10.1001/jama.2021.23182
Goldenberg, Neil A, et al. "Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial." JAMA vol. 327,2 (2022): 129-137. doi: https://doi.org/10.1001/jama.2021.23182
Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. PMID: 35015038.
Copy Download .nbib Format: NLM
Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Proteomics. Clinical applications

Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD.
PMID: 33915030
Proteomics Clin Appl. 2021 Sep;15(5):e2100003. doi: 10.1002/prca.202100003. Epub 2021 May 24.

PURPOSE: Sickle cell disease (SCD) is an inherited hemoglobinopathy that causes stroke and silent cerebral infarct (SCI). Our aim was to identify markers of brain injury in SCD.EXPERIMENTAL DESIGN: Plasma proteomes were analyzed using a sequential separation approach of...

Cite
Lance EI, Faulcon LM, Fu Z, et al. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021;15(5):e2100003doi: 10.1002/prca.202100003.
Lance, E. I., Faulcon, L. M., Fu, Z., Yang, J., Whyte-Stewart, D., Strouse, J. J., Barron-Casella, E., Jones, K., Van Eyk, J. E., Casella, J. F., & Everett, A. D. (2021). Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics. Clinical applications, 15(5), e2100003. https://doi.org/10.1002/prca.202100003
Lance, Eboni I, et al. "Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease." Proteomics. Clinical applications vol. 15,5 (2021): e2100003. doi: https://doi.org/10.1002/prca.202100003
Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021 Sep;15(5):e2100003. doi: 10.1002/prca.202100003. Epub 2021 May 24. PMID: 33915030; PMCID: PMC8666096.
Copy Download .nbib Format: NLM
Is Routine Invasive Monitoring Indicated in Surgery for the Morbidly Obese?.

Obesity surgery

Capella JF, Capella RF.
PMID: 10731250
Obes Surg. 1996 Feb;6(1):50-53. doi: 10.1381/096089296765557268.

BACKGROUND: Morbid obesity is generally considered to be a surgical and anesthetic risk. Some surgeons have advised the routine use of invasive monitoring for morbidly obese individuals undergoing surgery. The purpose of this study was to identify morbidly obese...

Cite
Capella JF, Capella RF. Is Routine Invasive Monitoring Indicated in Surgery for the Morbidly Obese?. Obes Surg. 1996;6(1):50-53doi: 10.1381/096089296765557268.
Capella, J. F., & Capella, R. F. (1996). Is Routine Invasive Monitoring Indicated in Surgery for the Morbidly Obese?. Obesity surgery, 6(1), 50-53. https://doi.org/10.1381/096089296765557268
Capella, and Capella. "Is Routine Invasive Monitoring Indicated in Surgery for the Morbidly Obese?." Obesity surgery vol. 6,1 (1996): 50-53. doi: https://doi.org/10.1381/096089296765557268
Capella JF, Capella RF. Is Routine Invasive Monitoring Indicated in Surgery for the Morbidly Obese?. Obes Surg. 1996 Feb;6(1):50-53. doi: 10.1381/096089296765557268. PMID: 10731250.
Copy Download .nbib Format: NLM
Ethnicity, Type of Obesity Surgery and Weight Loss.

Obesity surgery

Capella RF, Capella JF.
PMID: 10757949
Obes Surg. 1993 Nov;3(4):375-380. doi: 10.1381/096089293765559061.

In our study we compared weight loss among non-Hispanic whites (NHW), black Afro-Americans (BAA) and Hispanic Americans (HA) following vertical banded gastroplasty (VBG) and vertical banded gastroplastygastric bypass (VBG-RGB). From a total of 1222 patients, 662 qualified for the...

Cite
Capella RF, Capella JF. Ethnicity, Type of Obesity Surgery and Weight Loss. Obes Surg. 1993;3(4):375-380doi: 10.1381/096089293765559061.
Capella, R. F., & Capella, J. F. (1993). Ethnicity, Type of Obesity Surgery and Weight Loss. Obesity surgery, 3(4), 375-380. https://doi.org/10.1381/096089293765559061
Capella, and Capella. "Ethnicity, Type of Obesity Surgery and Weight Loss." Obesity surgery vol. 3,4 (1993): 375-380. doi: https://doi.org/10.1381/096089293765559061
Capella RF, Capella JF. Ethnicity, Type of Obesity Surgery and Weight Loss. Obes Surg. 1993 Nov;3(4):375-380. doi: 10.1381/096089293765559061. PMID: 10757949.
Copy Download .nbib Format: NLM
Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Proteomics. Clinical applications

Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD.
PMID: 33915030
Proteomics Clin Appl. 2021 Sep;15(5):e2100003. doi: 10.1002/prca.202100003. Epub 2021 May 24.

PURPOSE: Sickle cell disease (SCD) is an inherited hemoglobinopathy that causes stroke and silent cerebral infarct (SCI). Our aim was to identify markers of brain injury in SCD.EXPERIMENTAL DESIGN: Plasma proteomes were analyzed using a sequential separation approach of...

Cite
Lance EI, Faulcon LM, Fu Z, et al. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021;15(5):e2100003doi: 10.1002/prca.202100003.
Lance, E. I., Faulcon, L. M., Fu, Z., Yang, J., Whyte-Stewart, D., Strouse, J. J., Barron-Casella, E., Jones, K., Van Eyk, J. E., Casella, J. F., & Everett, A. D. (2021). Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics. Clinical applications, 15(5), e2100003. https://doi.org/10.1002/prca.202100003
Lance, Eboni I, et al. "Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease." Proteomics. Clinical applications vol. 15,5 (2021): e2100003. doi: https://doi.org/10.1002/prca.202100003
Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021 Sep;15(5):e2100003. doi: 10.1002/prca.202100003. Epub 2021 May 24. PMID: 33915030; PMCID: PMC8666096.
Copy Download .nbib Format: NLM
Vertical Banded Gastroplasty-Gastric Bypass: preliminary report.

Obesity surgery

Capella RF, Capella JF, Mandec H, Nath P.
PMID: 10775940
Obes Surg. 1991 Dec;1(4):389-395. doi: 10.1381/096089291765560782.

Vertical banded gastroplasty-gastric bypass is a surgical technique combining the advantages of the vertical banded gastroplasty with those of gastric bypass. The procedure was performed on 148 morbidly obese individuals: 83% were female, and 17% were male. Ages ranged...

Cite
Capella RF, Capella JF, Mandec H, et al. Vertical Banded Gastroplasty-Gastric Bypass: preliminary report. Obes Surg. 1991;1(4):389-395doi: 10.1381/096089291765560782.
Capella, R. F., Capella, J. F., Mandec, H., & Nath, P. (1991). Vertical Banded Gastroplasty-Gastric Bypass: preliminary report. Obesity surgery, 1(4), 389-395. https://doi.org/10.1381/096089291765560782
Capella, et al. "Vertical Banded Gastroplasty-Gastric Bypass: preliminary report." Obesity surgery vol. 1,4 (1991): 389-395. doi: https://doi.org/10.1381/096089291765560782
Capella RF, Capella JF, Mandec H, Nath P. Vertical Banded Gastroplasty-Gastric Bypass: preliminary report. Obes Surg. 1991 Dec;1(4):389-395. doi: 10.1381/096089291765560782. PMID: 10775940.
Copy Download .nbib Format: NLM
Incidence and pathogenesis of aneurysmal disease of the abdominal aorla.

Surgical technology international

Paik DC, Capella JF, Tilson MD.
PMID: 21319106
Surg Technol Int. 1994;3:393-8.

Abdominal aortic aneurysms (AAAs) are a major cause of illness and death in the United States and abroad. Along with progress in the surgical management of this condition, numerous advances have been made in understanding the pathogenesis of AAAs....

Cite
Paik DC, Capella JF, Tilson MD. Incidence and pathogenesis of aneurysmal disease of the abdominal aorla. Surg Technol Int. 1994;3:393-8
Paik, D. C., Capella, J. F., & Tilson, M. D. (1994). Incidence and pathogenesis of aneurysmal disease of the abdominal aorla. Surgical technology international, 3393-8.
Paik, D C, et al. "Incidence and pathogenesis of aneurysmal disease of the abdominal aorla." Surgical technology international vol. 3 (1994): 393-8.
Paik DC, Capella JF, Tilson MD. Incidence and pathogenesis of aneurysmal disease of the abdominal aorla. Surg Technol Int. 1994;3:393-8. PMID: 21319106.
Copy Download .nbib Format: NLM
Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Proteomics. Clinical applications

Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD.
PMID: 33915030
Proteomics Clin Appl. 2021 Sep;15(5):e2100003. doi: 10.1002/prca.202100003. Epub 2021 May 24.

PURPOSE: Sickle cell disease (SCD) is an inherited hemoglobinopathy that causes stroke and silent cerebral infarct (SCI). Our aim was to identify markers of brain injury in SCD.EXPERIMENTAL DESIGN: Plasma proteomes were analyzed using a sequential separation approach of...

Cite
Lance EI, Faulcon LM, Fu Z, et al. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021;15(5):e2100003doi: 10.1002/prca.202100003.
Lance, E. I., Faulcon, L. M., Fu, Z., Yang, J., Whyte-Stewart, D., Strouse, J. J., Barron-Casella, E., Jones, K., Van Eyk, J. E., Casella, J. F., & Everett, A. D. (2021). Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics. Clinical applications, 15(5), e2100003. https://doi.org/10.1002/prca.202100003
Lance, Eboni I, et al. "Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease." Proteomics. Clinical applications vol. 15,5 (2021): e2100003. doi: https://doi.org/10.1002/prca.202100003
Lance EI, Faulcon LM, Fu Z, Yang J, Whyte-Stewart D, Strouse JJ, Barron-Casella E, Jones K, Van Eyk JE, Casella JF, Everett AD. Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics Clin Appl. 2021 Sep;15(5):e2100003. doi: 10.1002/prca.202100003. Epub 2021 May 24. PMID: 33915030.
Copy Download .nbib Format: NLM
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

JAMA

Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S.
PMID: 35015038
JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182.

IMPORTANCE: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown.OBJECTIVE: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a...

Cite
Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022;327(2):129-137doi: 10.1001/jama.2021.23182.
Goldenberg, N. A., Kittelson, J. M., Abshire, T. C., Bonaca, M., Casella, J. F., Dale, R. A., Halperin, J. L., Hamblin, F., Kessler, C. M., Manco-Johnson, M. J., Sidonio, R. F., Spyropoulos, A. C., Steg, P. G., Turpie, A. G. G., Schulman, S. (2022). Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA, 327(2), 129-137. https://doi.org/10.1001/jama.2021.23182
Goldenberg, Neil A, et al. "Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial." JAMA vol. 327,2 (2022): 129-137. doi: https://doi.org/10.1001/jama.2021.23182
Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. PMID: 35015038.
Copy Download .nbib Format: NLM
Staple Disruption and Marginal Ulceration in Gastric Bypass Procedures for Weight Reduction.

Obesity surgery

Capella JF, Capella RF.
PMID: 10731249
Obes Surg. 1996 Feb;6(1):44-49. doi: 10.1381/096089296765557259.

BACKGROUND: Staple disruption is a frequent and serious complication of the segmentation procedures of gastric bypass surgery for weight reduction. Staple-line failure is frequently followed by weight gain and often marginal ulceration. METHODS: We reviewed the literature and analyzed...

Cite
Capella JF, Capella RF. Staple Disruption and Marginal Ulceration in Gastric Bypass Procedures for Weight Reduction. Obes Surg. 1996;6(1):44-49doi: 10.1381/096089296765557259.
Capella, J. F., & Capella, R. F. (1996). Staple Disruption and Marginal Ulceration in Gastric Bypass Procedures for Weight Reduction. Obesity surgery, 6(1), 44-49. https://doi.org/10.1381/096089296765557259
Capella, and Capella. "Staple Disruption and Marginal Ulceration in Gastric Bypass Procedures for Weight Reduction." Obesity surgery vol. 6,1 (1996): 44-49. doi: https://doi.org/10.1381/096089296765557259
Capella JF, Capella RF. Staple Disruption and Marginal Ulceration in Gastric Bypass Procedures for Weight Reduction. Obes Surg. 1996 Feb;6(1):44-49. doi: 10.1381/096089296765557259. PMID: 10731249.
Copy Download .nbib Format: NLM
Imaging Blood-Brain Barrier Permeability Through MRI in Pediatric Sickle Cell Disease: A Feasibility Study.

Journal of magnetic resonance imaging : JMRI

Lin Z, Lance E, McIntyre T, Li Y, Liu P, Lim C, Fan H, Tekes A, Cannon A, Casella JF, Lu H.
PMID: 34676938
J Magn Reson Imaging. 2021 Oct 22; doi: 10.1002/jmri.27965. Epub 2021 Oct 22.

BACKGROUND: Blood-brain barrier (BBB) disruption may lead to endothelium dysfunction and inflammation in sickle cell disease (SCD). However, abnormalities of BBB in SCD, especially in pediatric patients for whom contrast agent administration less than optimal, have not been fully...

Cite
Lin Z, Lance E, McIntyre T, et al. Imaging Blood-Brain Barrier Permeability Through MRI in Pediatric Sickle Cell Disease: A Feasibility Study. J Magn Reson Imaging. 2021;doi: 10.1002/jmri.27965.
Lin, Z., Lance, E., McIntyre, T., Li, Y., Liu, P., Lim, C., Fan, H., Tekes, A., Cannon, A., Casella, J. F., & Lu, H. (2021). Imaging Blood-Brain Barrier Permeability Through MRI in Pediatric Sickle Cell Disease: A Feasibility Study. Journal of magnetic resonance imaging : JMRI, . https://doi.org/10.1002/jmri.27965
Lin, Zixuan, et al. "Imaging Blood-Brain Barrier Permeability Through MRI in Pediatric Sickle Cell Disease: A Feasibility Study." Journal of magnetic resonance imaging : JMRI vol. (2021). doi: https://doi.org/10.1002/jmri.27965
Lin Z, Lance E, McIntyre T, Li Y, Liu P, Lim C, Fan H, Tekes A, Cannon A, Casella JF, Lu H. Imaging Blood-Brain Barrier Permeability Through MRI in Pediatric Sickle Cell Disease: A Feasibility Study. J Magn Reson Imaging. 2021 Oct 22; doi: 10.1002/jmri.27965. Epub 2021 Oct 22. PMID: 34676938.
Copy Download .nbib Format: NLM
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

JAMA

Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S.
PMID: 35015038
JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182.

IMPORTANCE: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown.OBJECTIVE: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a...

Cite
Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022;327(2):129-137doi: 10.1001/jama.2021.23182.
Goldenberg, N. A., Kittelson, J. M., Abshire, T. C., Bonaca, M., Casella, J. F., Dale, R. A., Halperin, J. L., Hamblin, F., Kessler, C. M., Manco-Johnson, M. J., Sidonio, R. F., Spyropoulos, A. C., Steg, P. G., Turpie, A. G. G., Schulman, S. (2022). Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA, 327(2), 129-137. https://doi.org/10.1001/jama.2021.23182
Goldenberg, Neil A, et al. "Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial." JAMA vol. 327,2 (2022): 129-137. doi: https://doi.org/10.1001/jama.2021.23182
Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. PMID: 35015038.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries